697 filings
Page 5 of 35
6-K
7yqnh6p pf
2 Nov 22
Report of Foreign Private Issuer
7:19am
6-K
11y6eo2
25 Oct 22
Report of Foreign Private Issuer
7:08am
6-K
net193yr43aexjjef8ok
12 Sep 22
Report of Foreign Private Issuer
7:02am
6-K
xps3oia4qc3voff
7 Sep 22
Report of Foreign Private Issuer
4:30pm
EFFECT
j173c
2 Sep 22
Notice of effectiveness
12:15am
6-K
b6ibtifc0s5
29 Aug 22
Report of Foreign Private Issuer
4:30pm
POS AM
tk29 4pp90
26 Aug 22
Prospectus update (post-effective amendment)
4:31pm
6-K
i8c fpi7x
25 Aug 22
Report of Foreign Private Issuer
7:16am
6-K
5wa6byaz ennfzr
23 Aug 22
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver
7:13am
6-K
tu0q9akuf
22 Aug 22
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
7:05am
6-K
trvv3ebhy
17 Aug 22
Report of Foreign Private Issuer
7:34am
6-K
6b2u2129clc10l g0jfz
25 Jul 22
Report of Foreign Private Issuer
4:30pm
6-K
vgmj5
11 Jul 22
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
7:13am
6-K
v1f 140qxye
29 Jun 22
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis
7:09am
6-K
sxiuj6zmkng
24 Jun 22
Report of Foreign Private Issuer
7:07am
6-K
3u1f9t3p32umb1rpjp
9 Jun 22
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
7:03am
6-K
7y8zb7 dv8w
26 May 22
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
7:18am
6-K
tg9n2h5 8q4
16 May 22
Can-Fite Granted Key NASH Patent in Israel
7:09am
6-K
rc7u pnbi
2 May 22
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
7:09am
6-K
r1ood7ig51axed rkk
5 Apr 22
Current Report of Foreign Private Issuer
7:08am